Gillet Jean-Pierre, de Longueville Françoise, Remacle José
University of Namur, URBC, 61 Rue de Bruxelles, 5000 Namur, Belgium.
Expert Rev Mol Diagn. 2006 May;6(3):295-306. doi: 10.1586/14737159.6.3.295.
Over the last 5 years, the emergence of gene expression profiling using high-density DNA microarrays led to a better understanding of tumor development and identified new prognostic markers. However, high-density microarrays failed to leap from the researcher's bench to the clinical practice due to their cost, data management and lack of standardization. DualChip low-density DNA microarrays were developed as a new flexible tool that is able to reliably quantify the expression of a limited number of genes of clinical relevance. This review will illustrate how DualChip technology can be applied to tumor diagnosis and tumor-acquired drug resistance.
在过去5年中，使用高密度DNA微阵列进行基因表达谱分析的出现，使人们对肿瘤发展有了更好的理解，并确定了新的预后标志物。然而，由于成本、数据管理和缺乏标准化，高密度微阵列未能从研究人员的工作台跃升至临床实践。双芯片低密度DNA微阵列作为一种新的灵活工具而被开发出来，它能够可靠地定量有限数量的具有临床相关性的基因的表达。本综述将阐述双芯片技术如何应用于肿瘤诊断和肿瘤获得性耐药。
